Aarey Drugs & Pharmaceuticals
NSE: AAREYDRUGS · ISIN INE198H01019 · Healthcare
₹107.45−1.76 (−1.61%)
Monday 9 November, 12:01 IST. Delayed. Source: Yahoo Finance.
Price chart
₹107.45 −1.76 (−1.61%) today
The day
- Previous close
- ₹109.21
- Open
- ₹109.75
- Day high
- ₹110.00
- Day low
- ₹106.69
Listed on NSE since 6 August 2021.
Key numbers
- Market value
- ₹343.35 Cr
- P/E (trailing)
- 73.28
- EPS (trailing)
- ₹1.47
- Price to book
- 2.04
- Dividend yield
- 0.00%
- Debt to equity
- 0.40
- Profit margin
- 0.9%
- Beta
- 1.20
- Volume today
- 5,690
- Average volume
- 2.18 L
Source: Yahoo Finance. Ratios use the latest reported (trailing twelve-month) figures.
Revenue and profit
| Year | Revenue | Net profit |
|---|---|---|
| FY23 | ₹412.85 Cr | ₹3.77 Cr |
| FY24 | ₹395.10 Cr | ₹4.68 Cr |
| FY25 | ₹472.44 Cr | ₹4.02 Cr |
| FY26 | ₹471.20 Cr | ₹3.97 Cr |
Source: Yahoo Finance, from annual reports. Consolidated where reported.
Quarterly results
| Quarter | Revenue | Net profit | Profit vs year ago |
|---|---|---|---|
| Q1 FY27Apr–Jun 2026 | ₹45 Cr | ₹1 Cr | −25.4% |
| Q4 FY26Jan–Mar 2026Audited | ₹189 Cr | ₹2 Cr | +231.3% |
| Q3 FY26Oct–Dec 2025 | ₹96 Cr | ₹56.95 L | – |
| Q2 FY26Jul–Sep 2025 | ₹84 Cr | ₹1 Cr | – |
| Q1 FY26Apr–Jun 2025 | ₹102 Cr | ₹1 Cr | – |
| Q4 FY25Jan–Mar 2025Audited | ₹108 Cr | ₹47.01 L | – |
Source: Aarey Drugs & Pharmaceuticals’s results filed with NSE, standalone (the company alone). Net profit is the share of Aarey Drugs & Pharmaceuticals’s own shareholders where the filing separates it. Profit vs year ago compares with the same quarter a year earlier; – where that quarter is not on file or made a loss. EPS before Q3 FY26 is not shown: the share count changed (a bonus, split or merger), so it would not compare.
Download results (zip) A spreadsheet of the quarterly results and balance sheets, with the original filings from NSE.
Balance sheet
| As on | March 2026 | September 2025 |
|---|---|---|
| Fixed assets | ₹26 Cr | ₹25 Cr |
| Investments | ₹2 Cr | ₹0 |
| Inventories | ₹42 Cr | ₹39 Cr |
| Owed by customers | ₹130 Cr | ₹122 Cr |
| Cash and equivalents | ₹1 Cr | ₹7 Cr |
| Total assets | ₹297 Cr | ₹294 Cr |
| Borrowings | ₹50 Cr | ₹51 Cr |
| Total liabilities | ₹147 Cr | ₹145 Cr |
| Shareholders’ equity | ₹150 Cr | ₹149 Cr |
Source: Aarey Drugs & Pharmaceuticals’s half-yearly statements of assets and liabilities filed with NSE, standalone. Companies file these every September and March.
About Aarey Drugs & Pharmaceuticals
Aarey Drugs & Pharmaceuticals Limited manufactures and sells active pharmaceutical ingredients, intermediates, and specialty chemicals for various industrial applications in India. The company offers intermediates, including mono methyl urea, di methyl urea, ortho para nitro anisole, 2-bromomethyl-1,3-dioxolane, and uracil. It also provides active pharmaceutical ingredients, such as metformin HCl, mefenamic acid, and doxofylline. In addition, the company trades chemicals and solvents, including aromatic chemicals, chemical acids, chlor-alkali, chlorinated solvent, glycols and glycol ethers, fiber intermediates, and acetates and esters, as well as industrial alcohols, ketones, amines, oleochemicals, intermediates, olefins, phosphates, fertilizers, monomers, and chemicals. Further, it offers lumefantrine; nimesulide; albendazole; carbamazepine; and oxcarbazepine. It serves pharmaceutical formulation manufacturers and pharmaceutical merchant exporters. Aarey Drugs & Pharmaceuticals Limited was incorporated in 1990 and is headquartered in Mumbai, India.
- Industry
- Drug Manufacturers - Specialty & Generic
- Based in
- Mumbai
Company website · Profile: Yahoo Finance
In the news
All newsNo headlines name Aarey Drugs & Pharmaceuticals in the last day or two.
Dividends and corporate actions
All companies- Annual General Meeting
Action · ex-date 23 September 2024
- Annual General Meeting
Action · ex-date 29 August 2023
- Annual General Meeting
Action · ex-date 22 September 2022
- Annual General Meeting
Action · ex-date 2 September 2021
Source: NSE. Latest first.
Information only, not investment advice. Prices are delayed.